To investigate the clinical relevance of RASD2 in thyroid cancer, we first analyzed RASD2 expression using the GEPIA database, which revealed significant upregulation in thyroid cancer tissues compared to normal controls (Figure 1A). This evidence concerns the gene RASD2 and thyroid gland carcinoma.